Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Optimizing scalable approaches for early detection of cognitive impairment in primary care.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

MethylCog predicts six-year cognitive ability beyond blood-based ADRD biomarkers.

medRxiv : the preprint server for health sciences·2026
Same author

Comparative analyses of Alzheimer's disease blood biomarkers and cognitive domains.

medRxiv : the preprint server for health sciences·2026
Same author

Development and validation of MethylCog, a blood DNA methylation proxy for cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Cognitive Fluctuations, Neuropsychiatric Burden, and Quality of Life in Moderate-Advanced Dementia With Lewy Bodies: The Role of Dysautonomia.

Neurology·2026
Same author

Associations between self-reported change in lifestyle behaviors and brain health: Findings from the Healthy Brain Initiative.

Journal of Alzheimer's disease : JAD·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

James E Galvin1, Tulimalefo'i Vaofanua2, Grace Grace Tuato'o2

  • 1University of Miami Miller School of Medicine, Boca Raton, FL, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

阿尔茨海默病 (AD) 和相关的痴呆症 (ADRD) 影响了美国萨摩亚31%的萨摩亚老人. 大多数认知障碍病例与AD病理学无关,这表明需要进行非AD生物标志物研究.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

科学领域:

  • 神经科学是一个神经科学.
  • 老年学是指老年学的学科.
  • 公共卫生 公共卫生

背景情况:

  • 普伊·马卢·马纳图研究调查了美国萨摩亚的阿尔茨海默病和相关痴呆症 (ADRD) 患病率,风险因素和生物标志物概况.
  • 本报告详细介绍了NIA资助的这项正在进行的研究的最初400名参与者的认知和生物标志物发现.

研究的目的:

  • 为了确定50岁及以上的萨摩亚老年人中ADRD的患病率.
  • 确定风险和弹性因素,并探索与认知衰退相关的遗传和血液生物标志物.
  • 在这个人群中评估健康素养和认知查工具.

主要方法:

  • 981名萨摩亚长老 (50岁以上) 的概率样本将使用UDSv3.0.0.进行金标准评估.
  • 将探索包括PrecivityAD2在内的遗传和血液生物标志物.
  • 认知功能将使用MoCA,Cognivue Clarity,QDRS和CDR-SB进行评估.

主要成果:

  • 队列 (平均年龄为60.4岁) 显示显著的认知障碍,其中31%的CDR-SB.得分为0.5+
  • 认知障碍患者年龄较大,男性,并发病率较高,MoCA分数较低.
  • ApoE ε4不是一个重要的风险因素,AD生物标志物 (Aβ42/40,pTau217) 在认知障碍组之间没有差异.

结论:

  • 认知障碍影响了美国萨摩亚31%的萨摩亚老人,大多数病例与AD病理学无关.
  • 在这个人群中,ApoE ε4似乎不是认知障碍的主要危险因素.
  • 进一步的研究应该探索非痴呆症生物标志物,文化定制的认知评估,以及个体内变化测量 (CDR) 对痴呆症检测的有用性.